Back to search results

ICG Angiogram for Visual Function After Brain Tumor Surgery

This study is looking at how a special dye called Indocyanine Green (ICG) can help doctors predict your vision after surgery for certain brain tumors. These tumors, like meningiomas, craniopharyngiomas, and pituitary adenomas, are located near your optic nerves (the nerves that help you see). During surgery, ICG is injected to help doctors see the blood flow around these nerves. The goal is to see if using ICG during surgery can help predict any vision problems you might have up to 6 weeks after the operation. You may be able to join if you are an adult (18 or older) having endonasal endoscopic surgery for one of these tumors.

Study design
This is an observational study involving 40 participants. It is not specified if it is randomized or blinded.
What's involved
You will undergo tumor resection surgery, during which Indocyanine Green (ICG) will be administered. Your vision will be assessed from surgery until your first post-operative follow-up at 6 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your vision will be followed up to 6 weeks after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06501716

ICG Angiogram as a Predictor of Postoperative Visual Function After EEA Surgery

UNKNOWN
Not specifiedAges 18+Observational
University of California, San Francisco
~40 participants
Updated 2024-07-22 on ClinicalTrials.gov
What's tested:Indocyanine Green

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Patients with Post Operative Visual Acuity Impairment and Visual Field Defect
Measured over From the surgery to first post-operative follow up (6 weeks)

Conditions

Indocyanine Green
Skull Base Neoplasms

Explore related trials

CraniopharyngiomaMeningiomaPituitary Neuroendocrine TumorSkull Base Neoplasm

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Ezequiel Goldschmidt, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

Ezequiel Goldschmidt, MD, PhD
[email protected]
415.514.6482
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

The study will enroll adult (18 y.o. and older) participants undergoing endonasal endoscopic surgery for suprasellar tumors including meningiomas, craniopharyngiomas and pituitary adenomas.

Exclusion

Underage patients (younger than 18 y.o).

What this trial measures

  • Percentage of Patients with Post Operative Visual Acuity Impairment and Visual Field DefectFrom the surgery to first post-operative follow up (6 weeks)

    The investigators will evaluate the percentage of participants that present with decreased of visual acuity and any modality of visual field defect after the surgery. Postoperative visual acuity and visual field testing will be performed at 6 weeks postoperative follow up visit to evaluate chiasm function, including cranial nerve examination, bilateral number counting, letter reading, and number identification in 4 quadrants of peripheral vision. Visual evaluations will be performed by the ophthalmology service following our standard postoperative protocol.